Rani Therapeutics Holdings-a (RANI) Institutional Ownership & 13F Filings (Q2 2026)

RANI ranks #5443 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

68 institutions disclose a position in RANI, but none treat it as a major bet — even Samsara BioCapital, LLC, its most concentrated holder, allocates just 0.7% of its own portfolio to it.

BNP Paribas Financial Markets has added to its RANI position for two straight quarters, increasing it by $1.6K to reach $1.6K today.

Susquehanna International Group, LLP has trimmed its RANI position for two straight quarters, cutting it by $2.7M while still holding $60.2K.

RANI is down 0.8% today, but institutions show net buying of $4.8M this quarter — a divergence between today's price move and the underlying institutional flow.

RANI reported a net loss of $30.1M over the trailing twelve months.

• Not yet profitable — net loss of $30.1M over the trailing twelve months
• Revenue grew 306.4% year over year
• Net income declined year over year, from -$29.7M to -$30.1M
• Operating cash flow was negative, using $18.7M in cash
• Current ratio of 4.21x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.52x equity — within a conventional range